{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:21:24Z","timestamp":1784193684702,"version":"3.55.0"},"reference-count":15,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mucosal malignant melanoma (MMM) is a rare subtype of malignant melanoma with a more aggressive biological behavior than cutaneous melanoma (CM). Owing to its rarity, it is necessary to accumulate information on treatments, especially in Asians, in whom MMM occurs more frequently than in Caucasians. In this study, we investigated the efficacy and adverse events (AEs) of nivolumab plus ipilimumab therapy (NIVO+IPI) versus immune checkpoint inhibitor (ICI) monotherapy (PD\u20101) in Japanese patients with MMM. We reviewed patients with advanced or recurrent MMM who received ICIs as first\u2010line systematic therapy between February 2012 and February 2024 at the Shizuoka Cancer Center. We enrolled a total of 57 patients: 10 (17.5%) were treated with NIVO+IPI, and 47 (82.5%) were treated with PD\u20101 as first\u2010line systemic therapy. Objective response rates (ORR) did not differ significantly between the NIVO+IPI and PD\u20101 groups (40.0% vs 27.7%; <jats:italic>p<\/jats:italic>\u2009=\u20090.176). There was also no statistically significant difference in progression\u2010free survival (PFS) (median PFS time: 4.3\u2009months vs 9.9\u2009months, log\u2010rank test, <jats:italic>p<\/jats:italic>\u2009=\u20090.578) or overall survival (OS) (median OS time: 33.1\u2009months vs. 22.8\u2009months, log\u2010rank test, <jats:italic>p<\/jats:italic>\u2009=\u20090.697) between the two groups. However, regarding AEs, grade\u2009\u22653 AEs leading to discontinuation of first\u2010line treatment occurred in 80% of patients in the NIVO+IPI group and in 22.6% of patients in the PD\u20101 group (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). No difference was found in the efficacy of NIVO+IPI therapy and anti\u2010PD\u20101 antibody monotherapy as the first\u2010line treatment for MMM in Japanese patients, but an increase in AEs was observed with combination therapy. This study suggests that patients with MMM may receive less benefit from NIVO+IPI than from PD\u20101.<\/jats:p>","DOI":"10.1111\/1346-8138.17445","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T14:51:58Z","timestamp":1726239118000},"page":"1425-1433","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of efficacy between anti\u2010<scp>PD<\/scp>\u20101 antibody monotherapy and nivolumab plus ipilimumab therapy as first\u2010line immunotherapy for advanced mucosal melanoma in Japanese patients: A single\u2010center, retrospective cohort study"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4497-6246","authenticated-orcid":false,"given":"Ken","family":"Horisaki","sequence":"first","affiliation":[{"name":"Department of Dermatology Shizuoka Cancer Center  Shizuoka Japan"},{"name":"Department of Dermatology Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shizuoka Cancer Center  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Omata","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shizuoka Cancer Center  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Tsutsumida","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shizuoka Cancer Center  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shizuoka Cancer Center  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"739","article-title":"Primary mucosal melanomas: a comprehensive review","volume":"5","author":"Mihajlovic M","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.09.054"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02303485"},{"key":"e_1_2_7_5_1","first-page":"38","article-title":"Treatment algorithm of metastatic mucosal melanoma","volume":"3","author":"Wang X","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.013"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920922028"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100325"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.10019"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16669"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.030"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:30:11Z","timestamp":1730521811000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/1346-8138.17445"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17445","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"2024-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}